FOXO4-DRI – Comprehensive Research Overview (2026)

FOXO4-DRI is a synthetic D-amino acid retro-inverso peptide designed to selectively induce apoptosis in senescent cells (cells that have stopped dividing but resist death). It is one of the most targeted senolytic agents developed, acting by disrupting the interaction between FOXO4 and p53 that keeps senescent cells alive. FOXO4-DRI is primarily researched for aging, age-related diseases, tissue rejuvenation, and conditions driven by senescent cell accumulation.

→ View FOXO4-DRI (for laboratory research use only)

Mechanism of Action

  • Penetrates senescent cells and disrupts the FOXO4–p53 protein-protein interaction.
  • Releases p53 from FOXO4 sequestration, allowing p53 to translocate to mitochondria and trigger apoptosis.
  • Selectively kills senescent cells while sparing healthy proliferating cells.
  • Reduces the senescence-associated secretory phenotype (SASP), decreasing chronic inflammation.
  • D-amino acid retro-inverso design confers protease resistance and enhanced stability.

Clinical Evidence and Research Findings

Preclinical studies in aged mice demonstrate restoration of fitness, fur density, and renal function after FOXO4-DRI treatment. Significant reductions in senescent cell burden and SASP markers were observed. No human clinical trials have been published as of April 2026, but it remains one of the most mechanistically precise senolytics in research. It is often compared to navitoclax and dasatinib+quercetin as a senolytic approach.

→ Interested in researching FOXO4-DRI? View Product Options

Benefits (Research & Clinical Observations)

  • Selective elimination of senescent cells
  • Reduced SASP and chronic inflammation
  • Restoration of tissue function in aging models
  • Improved physical fitness and organ function in preclinical studies
  • Potential for age-related disease and longevity research

Typical Dosing Protocols (Preclinical)

  • Preclinical mouse studies: 5 mg/kg IP or subcutaneous, 3 consecutive days per week for 2–3 weeks
  • Human equivalent dosing not established; no approved clinical protocols

Safety Profile

Favorable preclinical safety profile with selective targeting of senescent cells. No significant toxicity to healthy cells at effective doses in animal models. Human safety data are not available.

Summary

FOXO4-DRI is the most mechanistically precise senolytic peptide in research, selectively inducing apoptosis in senescent cells via FOXO4-p53 disruption. Its preclinical results in aging models are compelling, and it represents a leading tool in longevity and rejuvenation research. As with all compounds in this library, FOXO4-DRI is not an approved drug and should only be considered under qualified research supervision.

For Laboratory Research Use View FOXO4-DRI →

Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.